A Covid-19 vaccine candidate from China's Walvax Biotechnology using mRNA technology triggered a stronger antibody response against the Omicron variant of the coronavirus as a booster dose than Sinovac's shot, clinical trial data showed.

The result for Walvax's ARCoV candidate, which is yet to be peer-reviewed, comes as competition for the Covid-19 booster market intensifies in China, where more than...